Top Markets
#1 Black Phoenix Black Phoenix +735.06%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.97%
#3 TENDIES TENDIES +22.56%
#4 THORChain THORChain +18.08%
#5 Biconomy Biconomy +17.88%
#6 MetaDAO MetaDAO +17.62%
#7 Wrapped STX (Velar) Wrapped STX (Velar) +17.45%
#8 Moolah Moolah +15.45%
#9 Pons Pons +13.77%
#10 THORChain Yield THORChain Yield +13.47%
Coin of the day
Black Phoenix Black Phoenix
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Keymed Biosciences Inc. Keymed Biosciences Inc.

Keymed Biosciences Inc.

2162
Classement en actions #5165
Keymed Biosciences Inc., a biotechnology firm founded in 2016 in Chengdu, China... Keymed Biosciences Inc., a biotechnology firm founded in 2016 in Chengdu, China (formerly known as 2Health Biosciences, Inc.), specializes in the research and development of innovative biological treatments, primarily targeting autoimmune and oncology diseases. A cornerstone of their pipeline is CM310, their lead product candidate, which is currently being developed for the management of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). Complementing this, the company is also progressing CM326, a monoclonal antibody designed to inhibit thymic stromal lymphopoietin, for similar indications such as AD, CRSwNP, asthma, and COPD. In the realm of oncology, Keymed is developing CMG901 for solid tumors, particularly those affecting the stomach and gastroesophageal junction. Another significant candidate, CM313, is a humanized monoclonal antibody slated for the treatment of relapsed or refractory multiple myeloma, lymphoma, other blood cancers, and systemic lupus erythematosus. Their extensive portfolio further includes MIL95/CM312, a humanized monoclonal antibody targeting CD47; CM338, an antagonist antibody against mannose-binding lectin-associated serine protease-2; CM355, intended for relapsed or refractory non-Hodgkin's lymphoma; CM336, for multiple myeloma; CM350, for various solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody.
Prix de l'action
$9.91
Capitalisation boursière
$2.92B
Changement (1 jour)
-3.25%
Changement (1 an)
16.09%
Pays
CN
Échange Keymed Biosciences Inc. (2162)

Catégorie

Healthcare
Bénéfices pour Keymed Biosciences Inc. (2162)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Keymed Biosciences Inc., les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Keymed Biosciences Inc. de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH